We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

46 hedge funds and large institutions have $13.4M invested in Aptose Biosciences in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

1.74% less ownership

Funds ownership: 26.73% → 24.99% (-1.7%)

6% less funds holding

Funds holding: 49 → 46 (-3)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

67% less capital inflows, than outflows

Capital inflows: $469K | Capital outflows: $1.44M

Holders
46
Holders Change
-3
Holders Change %
-6.12%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
10
Closed
9
Calls
$32​K
Puts
–
Net Calls
+$32​K
Net Calls Change
+$4​K

APTO Hedge Fund Activity: Q4 2022 in Review

46 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q4 2022, worth a combined $13.4M — down 8.9% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of APTO and 5 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was Sigma Planning, adding an estimated $102K. The largest seller was Nantahala Capital Management, cutting an estimated $499K.

  • 46 institutional investors held Aptose Biosciences (APTO) as of Q4 2022, down from 49 in Q3 2022.
  • Funds reported $13.4M of Aptose Biosciences stock for Q4 2022, down 8.9% quarter-over-quarter.
  • 5 funds opened new Aptose Biosciences positions in Q4 2022 and 9 closed out, a net change of -4 holders.
  • The largest Aptose Biosciences buyer in Q4 2022 was Sigma Planning, an estimated $102K added.
  • The largest Aptose Biosciences seller in Q4 2022 was Nantahala Capital Management, an estimated $499K sold.

Based on aggregated 13F filings for Q4 2022.